Ipilimumab/nivolumabHypophysitis and type 1 diabetes: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1608卷 / 1期

关键词：

D O I：

10.1007/s40278-016-19172-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：160 / 160

相关论文

共 50 条

[21] Ipilimumab/NivolumabHypophysitis
[J]. Reactions Weekly, 2024, 2003 (1) : 477 - 477
[22] Ipilimumab/nivolumabHypophysitis: 3 case reports
[J]. Reactions Weekly, 2020, 1833 (1) : 216 - 216
[23] Ipilimumab/nivolumabHypophysitis: 25 case reports
[J]. Reactions Weekly, 2021, 1859 (1) : 197 - 197
[24] Ipilimumab/nivolumabHypophysitis: 5 case reports
[J]. Reactions Weekly, 2017, 1639 (1) : 169 - 169
[25] Ipilimumab/nivolumabHypophysitis and Raynaud's-like phenomenon: case report
[J]. Reactions Weekly, 2020, 1816 (1) : 190 - 190
[26] Ipilimumab/nivolumabHypophysitis
[J]. Reactions Weekly, 2024, 2011 (1) : 226 - 226
[27] Ipilimumab/nivolumabDestructive thyroiditis and type 1 diabetes mellitus: case report
[J]. Reactions Weekly, 2021, 1862 (1) : 261 - 261
[28] Ipilimumab/nivolumabColitis, hyperthyroidism and type 1 diabetes mellitus: case report
[J]. Reactions Weekly, 2018, 1705 (1) : 174 - 174
[29] Ipilimumab/levothyroxine sodium/nivolumabHypophysitis, adrenal insufficiency and syncopal episode: case report
[J]. Reactions Weekly, 2017, 1652 (1) : 159 - 159
[30] Ipilimumab/nivolumabType 1 diabetes: case report
[J]. Reactions Weekly, 2018, 1726 (1) : 216 - 216

← 1 2 3 4 5 →